Melflufen

10 records found.

Sep 15, 2019

New Interim Data in RRMM Patients With Extramedullary Disease from the Pivotal Phase 2 Horizon-study Presented at International Myeloma Workshop

Aug 16, 2019

Oncopeptides Announces Acceptance of Data for Presentation at International Myeloma Workshop, September 12-15

Jun 16, 2019

New Data Presented from Oncopeptides' Pivotal Phase 2 HORIZON Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma at 24th EHA Congress

Jun 14, 2019

New Data Presented at 24th EHA Congress From Oncopeptides' Phase 1/2 ANCHOR Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma (RRMM)

Jun 03, 2019

New Data from Oncopeptides Phase 1/2 O-12-M1 Trial Evaluating Melflufen in RRMM Presented at 2019 ASCO Annual Meeting

May 20, 2019

Oncopeptides to Apply for Accelerated Approval in the US

May 16, 2019

Oncopeptides Announces Acceptance of Four Abstracts Highlighting Melflufen Clinical Programs for Presentation at 24th EHA Congress in June 2019

Feb 27, 2019

Data From Oncopeptides Clinical Trials HORIZON and ANCHOR Evaluating Melflufen in RRMM Selected for Presentation at the AACR Annual Meeting

Dec 02, 2018

Oncopeptides Presents First Interim Data From the Ongoing Combination Trial ANCHOR With Melflufen at the 60th American Society of Hematology Meeting

Nov 01, 2018

Oncopeptides to Present Updated Data From the Two Ongoing Trials ANCHOR and HORIZON in Patients with RRMM at ASH in December 2018